



August 31, 2017

SCYNEXIS to Present at Upcoming Investor Conferences

JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

- | Baird's 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Thursday, September 7, 2017 at 8:30 a.m. ET.
- | The Rodman & Renshaw 19th Annual Global Investment Conference at the Lotte New York Palace Hotel on Monday, September 11, 2017 at 9:35 a.m. ET.
- | The Cantor Fitzgerald 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 27, 2017 at 11:30 a.m. ET.

Live webcasts of each presentation will be available on the investors section of the Company's website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, [SCY-078](#), is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.

CONTACT:

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com

Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com